David Wang
Director/Board Member at BIOVAXYS TECHNOLOGY CORP.
Net worth: 92 540 $ as of 2024-04-29
Profile
David Wang is currently the Chief Executive Officer at Encounter Technology Ltd., Director at BioVaxys Technology Corp., and Director at BioVaxys LLC.
Previously, he worked as the Chief Executive Officer at Beijing Century Medical.
Mr. Wang holds an MBA from the University of International Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BIOVAXYS TECHNOLOGY CORP
1.03% | 2023-02-07 | 1,492,575 ( 1.03% ) | 92 540 $ | 2024-04-29 |
David Wang active positions
| Companies | Position | Start |
|---|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Director/Board Member | - |
BioVaxys LLC
 BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Director/Board Member | - |
| Encounter Technology Ltd. | Chief Executive Officer | - |
Former positions of David Wang
| Companies | Position | End |
|---|---|---|
| Beijing Century Medical | Chief Executive Officer | - |
Training of David Wang
| University of International Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Non-Energy Minerals |
| Private companies | 3 |
|---|---|
BioVaxys LLC
BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Health Technology |
| Beijing Century Medical | |
| Encounter Technology Ltd. |
- Stock Market
- Insiders
- David Wang